February 7, 2007 - Siemens Medical Solutions today opened the doors to a new molecular imaging biomarker research site, Siemens Medical Solutions Molecular Imaging (MI) Biomarker Research facility, as Siemens strives to become the world's first full-service diagnostics company, integrating in vivo and in vitro imaging diagnostics capabilities.
At the new facility, researchers will be dedicated exclusively to the development of molecular imaging biomarkers. The goal of the research is to spur the growth of in vivo molecular diagnostics, in which in vivo diagnostic tools are designed to identify debilitating diseases such as cancer and neurological diseases at their earliest stages. The biomarkers bind to the diseased cells or tissues and cause them to "light up" when scanned using PET-CT (Positron Emission Tomography-Computed Tomography) or SPECT-CT (Single-Photon Emission Computed Tomography).
Siemens' goal is to bring several new agents to the market over the next 5 - 10 years. Research and development efforts conducted at the facility will focus
largely on oncology and neurology, and also include other areas such
as inflammation and microfluidics/nanotechnology research.

"Molecular medicine is heralding a new era in diagnostic capabilities that could change the lives of millions of Americans, and Siemens is helping lead the field out of the research lab and into practical use," said Michael Reitermann, president, Molecular Imaging division, Siemens Medical Solutions. "Advancing this field brings with it the promise of personalized therapeutics, which would not only improve the efficiency of health care, but most importantly, would also improve the quality of health care for patients."
The opening of the site is the latest step for the company in becoming Siemens recently launched Siemens Medical Solutions Diagnostics as the in vitro complement to the portfolio on the heels of acquisitions of Bayer Diagnostics and Los Angeles-based Diagnostic Products Corporation.


Related Content

News | PET-CT

July 16, 2024 — A new research paper was published in Oncotarget's Volume 15 on June 20, 2024, titled, “Comparison of ...

Time July 16, 2024
arrow
News | Nuclear Imaging

June 20, 2024 — GE HealthCare joined the world’s top medical and academic institutions at the Society of Nuclear ...

Time June 20, 2024
arrow
News | PET-CT

June 13, 2024 — Positron Corporation, a leading molecular imaging medical device company offering PET and PET-CT ...

Time June 13, 2024
arrow
News | Radiopharmaceuticals and Tracers

April 5, 2024 — RLS Radiopharmacies, America’s only Joint Commission-accredited radiopharmacy network, today announced ...

Time April 05, 2024
arrow
News | SPECT Imaging

February 15, 2024 — According to a release issued by the U.S. Food and Drug Administration (FDA), Philips is recalling ...

Time February 15, 2024
arrow
News | FDA

January 23, 2024 — Siemens Healthineers announces the Food and Drug Administration (FDA) clearance of syngo Virtual ...

Time January 23, 2024
arrow
Feature | PET-CT | By Melinda Taschetta-Millane

According to research conducted by Polaris Market Research, the global positron emission tomography (PET)/computed ...

Time January 17, 2024
arrow
News | Prostate Cancer

January 5, 2024 — Perspective Therapeutics, Inc., announced that it has entered into a patent license agreement with ...

Time January 05, 2024
arrow
News | Radiopharmaceuticals and Tracers

December 6, 2023 — Philochem AG, a wholly owned subsidiary of Philogen S.p.A., and Blue Earth Diagnostics, a Bracco ...

Time December 06, 2023
arrow
News | RSNA

December 1, 2023 — In today's healthcare environment, the industry faces various pressing challenges. The magnetic ...

Time December 01, 2023
arrow
Subscribe Now